Physician profile
Patrick K Hayden
NPI 1295847184
$788.26
in general payments reported to CMS, 2019-2025
19 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $68.27 · 2021: $115 · 2022: $12.88 · 2023: $154 · 2024: $213 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $478.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $125.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $104.14 | 2019-2023 | |
| Vifor Pharma, INC. | $91.46 | 2019-2020 | |
| Abbvie INC. | $81.10 | 2023-2025 | |
| Amgen INC. | $49.23 | 2023-2024 | Otezla, Repatha |
| Lilly USA, LLC | $43.74 | 2019-2024 | Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $37.76 | 2024 | |
| Pfizer INC. | $34.57 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $31.77 | 2021 | |
| Medtronic, INC. | $28.99 | 2024 | Endurant Iis |
| Glaxosmithkline, LLC. | $26.35 | 2024 | Trelegy Ellipta, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.14 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $19.19 | 2024 | Voquezna |
| Lundbeck LLC | $18.04 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $17.18 | 2025 | Auvelity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $16.89 | 2023 | Rexulti |
| Esperion Therapeutics, INC. | $15.32 | 2024 | Nexletol |
| Paratek Pharmaceuticals, INC. | $14.52 | 2024 | Nuzyra |
| Abbott Laboratories | $12.74 | 2023 | Id Now Instrument |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Hayden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.